Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Mycifradin

(Neomycin)

ApprovedSmall molecule

PPharmacia and Upjohn

Neomycin is an antibiotic used to treat bacterial infections, particularly ear and eye infections, and is also used to reduce bacteria in the intestines before surgery or to help treat certain liver conditions.[2] Mycifradin is currently approved and in use across 14 indications[4].[1]

Mycifradin is one of 367 small molecule programs targeting Metabolic Syndrome. It is currently in Approved.

14

Indications

22

Total Trials

4

Active Trials

366

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Metabolic SyndromeActive, not recruiting

Bacterial DiseaseActive, not recruiting

PneumoniaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Prediabetes SyndromeApproved

EncephalopathyActive, not recruiting

Eye InfectionActive, not recruiting

Biliary AtresiaActive, not recruiting

OsteomyelitisApproved

Rectum CancerApproved

Metabolic SyndromePhase 2

Active, not recruiting

Bacterial DiseaseApproved

Active, not recruiting

PneumoniaPreclinical

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Prediabetes SyndromeApproved

Approved

EncephalopathyPreclinical

Active, not recruiting

Eye InfectionApproved

Active, not recruiting

Biliary AtresiaPreclinical

Active, not recruiting

OsteomyelitisApproved

Approved

Rectum CancerApproved

Approved

Showing 10 of 13 indications

Competition

Competitive Landscape

698 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Vectibix

Mycifradin

PPharmacia and Upjohn

Sutent

SU5416

Folinic Acid

Innohep

Alnylam Pharmaceuticals

Cecon

MMcGuff Pharmaceuticals, Inc.

Fusilev

DDurata Therapeutics International BV (an Affiliate of Actavis, Inc.)

Xeloda

Vatalanib

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Heart Failure

NCT07490054

Q4 2027

Phase 2Active, not recruiting

Metastatic Colorectal Cancer

NCT04729322

Q4 2028

Post-ApprovalRecruiting

Immune Response

NCT06148025

Q2 2029

Post-ApprovalNot yet recruiting

Colon Surgery

NCT07180615

Clinical

Trials by Indication[1]

Antibiotics3 trials

Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics

Completed·EEmory University·N/A·NCT02154061·33 enrolled

Responses to Rabies Vaccine in Adults With or Without Antibiotics

Completed·EEmory University·Phase 4·NCT03557008·37 enrolled

Do Topical Antibiotics Improve Skin Graft Results?

Completed·LLAMB Project··NCT07286851·142 enrolled

Crohn's Disease2 trials

Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

Completed·—·Phase 2·NCT03476317·10 enrolled

Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

Completed·UUniversity of Pennsylvania·Phase 2·NCT02765256·8 enrolled

Colorectal Surgery2 trials

Bowel Preparation in Elective Pediatric Colorectal Surgery

Unknown status·MMcMaster University·N/A·NCT03593252·81 enrolled

Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery

Unknown status·TThomas Jefferson University·Phase 1·NCT03042091·224 enrolled

Complication1 trial

SURGIcal COmplication and MIcrobiome ChangeS in Colorectal Surgery

Unknown status·—··NCT05779254·100 enrolled

Colon Surgery1 trial

Gut Decolonisation With Neomycin/Metronidazole or Rifaximin Before Colon Surgery

Not yet recruiting·—·Phase 4·NCT07180615·458 enrolled

13 more indications

Irritable Bowel Syndrome1 trial

Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome

Completed·MMark Pimentel, MD·N/A·NCT00945334·37 enrolled

Encephalopathy1 trial

Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy

Unknown status·UUPECLIN HC FM Botucatu Unesp·N/A·NCT01097811·20 enrolled

Tics1 trial

Effect of Neomycin on the Pharmacokinetics of Regorafenib

Completed· Bayer logo

Bayer·Phase 1·NCT02001909·27 enrolled

Ulcerative Colitis1 trial

Antibiotics for the Treatment of Ulcerative Colitis

Completed·UUniversity of Dundee·N/A·NCT00355602·40 enrolled

Colonization1 trial

Decolonization of Carbapenem-resistant Enterobacterales (CRE) in Patients With Faecal Carriage of CRE With Neomycin

Unknown status·MMahidol University·Phase 4·NCT05593601·60 enrolled

Metastatic Colorectal Cancer1 trial

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04729322·15 enrolled

Biliary Atresia1 trial

Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia After the Kasai Portoenterostomy

Completed·NNational Taiwan University Hospital·N/A·NCT00166868·30 enrolled

Metabolic Syndrome1 trial

Interventional Bioremediation of Microbiota in Metabolic Syndrome

Terminated·UUniversity of Minnesota·Phase 2·NCT02730962·12 enrolled

Antibiotic-resistant Bacteria1 trial

Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy

Unknown status·SStephen Harbarth·Phase 2·NCT02472600·39 enrolled

Pneumonia1 trial

Efficacy of Intestinal Decontamination in Patients Colonized by Carbapenem-resistant Klebsiella Pneumoniae and Colistin

Completed·MMaimónides Biomedical Research Institute of Córdoba··NCT02604849·44 enrolled

Heart Failure1 trial

Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure

Recruiting·MMelana Yuzefpolskaya, MD·Phase 1·NCT07490054·40 enrolled

Immune Response1 trial

Antibiotics and Vaccine Immune Responses Study

Recruiting·SSouth Australian Health and Medical Research Institute·Phase 4·NCT06148025·348 enrolled

Unspecified1 trial

Role of Methane in Glycemic Control

Completed·—·Phase 1·NCT01638429·11 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

MYCIFRADIN

NDA NDA050285

Sources

References

[1]
ClinicalTrials.gov — 22 trial records for Neomycin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Mycifradin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Neomycin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Neomycin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA050285). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Pharmacia and Upjohn company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Bacterial 70s Ribosome Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: PPharmacia and Upjohn

Related News